Literature DB >> 3347938

HLA antigens in ocular tissues. I. In vivo expression in human eyes.

D Abi-Hanna1, D Wakefield, S Watkins.   

Abstract

The eye is a common site for autoimmune inflammatory diseases, many of which are linked to HLA antigens. The role of these HLA phenotypes in the disease process is presently unknown. In view of the importance of HLA antigens to immune responses, a knowledge of the distribution of HLA antigens in ocular tissues may aid in our understanding of the role of these antigens in disease production or susceptibility. Apart from the cornea, the expression of HLA antigens in human ocular tissues has not been thoroughly investigated. In this study we examined the in vivo expression of HLA antigens in postmortem human eyes using immunohistochemical techniques. The majority of ocular cells were found not to express class I or class II HLA antigens, with the exception of the blood vessel endothelium, which was uniformly class I-positive. The significance of these results is discussed in relation to ocular immunity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3347938     DOI: 10.1097/00007890-198803000-00021

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  21 in total

1.  HLA class II genotypes are not associated with age related macular degeneration in a case-control, population-based study.

Authors:  Derek Pappas; Jill Hollenbach; Anne L Coleman; Michael B Gorin; Fe Yu; Kevin Williams; Janelle Noble; Gregory J Tranah
Journal:  Hum Immunol       Date:  2015-02-07       Impact factor: 2.850

Review 2.  Translational Immunoimaging and Neuroimaging Demonstrate Corneal Neuroimmune Crosstalk.

Authors:  Pedram Hamrah; Yashar Seyed-Razavi; Takefumi Yamaguchi
Journal:  Cornea       Date:  2016-11       Impact factor: 2.651

Review 3.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

4.  The influence of penetrating keratoplasty and cyclosporin A therapy on MHC class II (Ia)-positive cells in the rat iris and choroid.

Authors:  S E Coupland; L Krause; F Hoffmann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-02       Impact factor: 3.117

5.  Cross-matches on donor cadaver retinal pigment epithelial cells in corneal risk patients.

Authors:  N Zavazava; B Nölle; G Duncker; S Jenisch; E Westphal; V Eckstein; W Müller-Ruchholtz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-03       Impact factor: 3.117

6.  CD4-mediated and CD8-mediated cytotoxic and proliferative immune responses to Toxoplasma gondii in seropositive humans.

Authors:  M B Purner; R L Berens; P B Nash; A van Linden; E Ross; C Kruse; E C Krug; T J Curiel
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

7.  Preparation and evaluation of human choroid extracellular matrix scaffolds for the study of cell replacement strategies.

Authors:  Kathleen R Chirco; Kristan S Worthington; Miles J Flamme-Wiese; Megan J Riker; Joshua D Andrade; Beatrix M Ueberheide; Edwin M Stone; Budd A Tucker; Robert F Mullins
Journal:  Acta Biomater       Date:  2017-05-05       Impact factor: 8.947

Review 8.  Influence of immune privilege on ocular tumor development.

Authors:  Kyle C McKenna; Peter W Chen
Journal:  Ocul Immunol Inflamm       Date:  2010-04       Impact factor: 3.070

Review 9.  Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy.

Authors:  S Scott Whitmore; Elliott H Sohn; Kathleen R Chirco; Arlene V Drack; Edwin M Stone; Budd A Tucker; Robert F Mullins
Journal:  Prog Retin Eye Res       Date:  2014-12-05       Impact factor: 21.198

10.  A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma.

Authors:  B Gaugler; N Brouwenstijn; V Vantomme; J P Szikora; C W Van der Spek; J J Patard; T Boon; P Schrier; B J Van den Eynde
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.